Dexrazoxane Prevents Anthracycline-Related Cardiotoxicity in Childhood AML
New data from researchers at the Children’s Hospital of Philadelphia (CHOP) suggests use of dexrazoxane could provide some much-needed cardiovascular protection to pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML).